ISSN: 2459 - 1777 | E-ISSN 2587-0394

Quick Search




Long-term Results of Ranibizumab, Dexamethasone Implant, and Triamcinolone in Macular Edema due to Branch Retinal Vein Occlusion [Beyoglu Eye J]
Beyoglu Eye J. 2019; 4(3): 141-148 | DOI: 10.14744/bej.2019.40412

Long-term Results of Ranibizumab, Dexamethasone Implant, and Triamcinolone in Macular Edema due to Branch Retinal Vein Occlusion

Nevin Hande Dikel1, Erhan Yumusak2, Nesrin Buyuktortop Gokcinar3
1Department of Ophthalmology, Karaman State Hospital, Karaman, Turkey
2Department of Ophthalmology, University of Health Sciences, Gulhane Faculty of Medicine, Ankara, Turkey
3Department of Ophthalmology, Kirikkale University Faculty of Medicine, Kirikkale, Turkey

INTRODUCTION: The present study aims to compare the long-term efficacy and safety results of intravitreal ranibizumab (RAN), dexamethasone intravitreal implant (DEX) and intravitreal triamcinolone acetonide (IVTA) injections in macular edema due to branch retinal vein occlusion (BRVO).
METHODS: In this retrospective study, one eye each of 43 patients who were treated with intravitreal injections for macular edema secondary to BRVO was recruited into one of the study groups: RAN group (n=17), DEX group (n=16) and IVTA group (n=10). All patients were followed-up for 12 months. Best-corrected visual acuity (BCVA), central macular thickness (CMT), subfoveal choroidal thickness (SFCT) and intraocular pressure (IOP) at month 1, 3, 6, and 12 were compared with baseline.
RESULTS: The BCVA increased significantly in the RAN and DEX groups at all visits (all p<0.05). BCVA increase in the IVTA group was significant only at month 1 and 6. CMT decreased significantly in all groups at the end of one year of follow-up (p=0.007; p=0.001; p=0.044, respectively). SFCT significantly decreased in all groups at month 1 (all p<0.05). IOP significantly increased in none, 18.8%, 30% of the patients in the RAN, DEX and IVTA groups, respectively. Cataract surgery was performed in none of the patients, 6.3%, and 30% of the patients in the RAN, DEX, and IVTA groups, respectively.
DISCUSSION AND CONCLUSION: BCVA increase was more prominent in both of the RAN and DEX groups than in the IVTA group. DEX may decrease the injection burden; however, ranibizumab may be a safer choice.

Keywords: Branch retinal vein occlusion, dexamethasone intravitreal implant, macular edema, ranibizumab, triamcinolone acetonide.

Nevin Hande Dikel, Erhan Yumusak, Nesrin Buyuktortop Gokcinar. Long-term Results of Ranibizumab, Dexamethasone Implant, and Triamcinolone in Macular Edema due to Branch Retinal Vein Occlusion. Beyoglu Eye J. 2019; 4(3): 141-148

Corresponding Author: Nesrin Buyuktortop Gokcinar, Türkiye
LookUs & Online Makale